{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-023680","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.065331+00:00","generated_at":"2026-06-11T11:54:19.983790+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Reviva Q2 net loss $12.4M; cash $11.2M; Phase 3 schizophrenia data due Oct 2023","bullets":["Net loss of $12.4M ($0.55 per share) for Q2 2023 vs $5.3M ($0.29) a year ago.","Cash $11.2M as of June 30, 2023, down from $18.5M at Dec 2022; runway into Q4 2023.","Topline data for pivotal Phase 3 RECOVER trial of brilaroxazine in schizophrenia expected October 2023.","Enrollment near completion (~400 patients); 1-year OLE study completion expected Q3 2024.","May initiate Phase 2a studies in bipolar, MDD, ADHD in H2 2023 subject to additional financing."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-023680","json":"https://secwatch.observer/filing/0001437749-23-023680.json","markdown":"https://secwatch.observer/filing/0001437749-23-023680.md","text":"https://secwatch.observer/filing/0001437749-23-023680.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923023680/0001437749-23-023680-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923023680/rvph20230809_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T11:54:19.983790+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c2773eb068953e70d512edab7b5590fe6d601083","claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. reported six months ended June 30, 2023 results: net income net loss of approximately $19.0 million, EPS ($0.86) per share.","evidence_excerpt":"The Company reported a net loss of approximately $19.0 million, or ($0.86) per share, for the six months ended June 30, 2023, compared to a net loss of approximately $12.7 million, or ($0.69) per share, for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923023680/0001437749-23-023680-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"six months ended June 30, 2023"},{"label":"Net income","value":"net loss of approximately $19.0 million"},{"label":"EPS","value":"($0.86) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ff04b2c6e203dd095a8db7db41414705aaf3183c","claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. reported second quarter ended June 30, 2023 results: net income net loss of approximately $12.4 million, EPS ($0.55) per share.","evidence_excerpt":"The Company reported a net loss of approximately $12.4 million, or ($0.55) per share, for the three months ended June 30, 2023, compared to a net loss of approximately $5.3 million, or ($0.29) per share, for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923023680/0001437749-23-023680-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Net income","value":"net loss of approximately $12.4 million"},{"label":"EPS","value":"($0.55) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}